Literature DB >> 28786877

Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): Further Morphologic and Molecular Characterization of ESC RCC as a Distinct Entity.

Kiril Trpkov1, Hatem Abou-Ouf, Ondřej Hes, Jose I Lopez, Gabriella Nesi, Eva Comperat, Mathilde Sibony, Adeboye O Osunkoya, Ming Zhou, Neriman Gokden, Xavier Leroy, Daniel M Berney, Isabela Werneck Cunha, Maria L Musto, Daniel A Athanazio, Asli Yilmaz, Bryan Donnelly, Eric Hyndman, Anthony J Gill, Jesse K McKenney, Tarek A Bismar.   

Abstract

Eosinophilic solid and cystic renal cell carcinoma (ESC RCC) has been recently described as a unique and indolent renal neoplasm, found in female patients with and without tuberous sclerosis complex. Although ESC RCC has a distinct morphology and frequent CK20 reactivity, its molecular karyotype has been previously studied only in few cases. We identified 19 ESC RCC from multiple institutions; all patients were female individuals without clinical features of tuberous sclerosis complex. Molecular karyotyping was performed in 13 cases (12 with informative result). The median age was 55 years (range: 32 to 79 y). The tumors were yellow-gray with a median size of 31 mm (range: 12 to 135 mm) and showed solid and cystic gross appearance. All tumors demonstrated typical microscopic features with solid areas admixed with variably sized macrocysts and microcysts. The cells showed eosinophilic cytoplasm with granular cytoplasmic stippling and round-to-oval nuclei. CK20 was positive in 14/19 (74%) cases. Stage pT1 was found in 17/19 (89%) patients (pT1a in 12, pT1b in 5); 1 patient each had pT2a and pT3a. A total of 15/16 patients with available follow-up were alive and without evidence of disease progression, after 1 to 169 months (median: 44 mo; mean: 49.6 mo); 3 died of other causes. The most common copy number gains were 16p13.3-16q23.1 (33% to 67%), 7p21.2-7q36.2 (42% to 50%), 13q14.2 (33%), and 19p12 (33%). The most common copy number losses included Xp11.21 (42%) and 22q11.23 (33%). Loss of heterozygosity was most frequently found at 16p11.2-11.1 (75%), Xq11.1-13.1 (75%), Xq13.1-21.1 (33%), 11p11.2-11.11 (33%), 9q21.1-22.2 (33%), and 9q33.1 (33%). ESC RCC demonstrates common molecular karyotype alterations, which further support its distinct nature.

Entities:  

Mesh:

Year:  2017        PMID: 28786877     DOI: 10.1097/PAS.0000000000000838

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  22 in total

1.  "High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.

Authors:  Huiying He; Kiril Trpkov; Petr Martinek; Ozlem Tanas Isikci; Cristina Maggi-Galuzzi; Reza Alaghehbandan; Anthony J Gill; Maria Tretiakova; Jose Ignacio Lopez; Sean R Williamson; Delia Perez Montiel; Maris Sperga; Eva Comperat; Fadi Brimo; Ali Yilmaz; Kristyna Pivovarcikova; Kveta Michalova; David Slouka; Kristyna Prochazkova; Milan Hora; Michael Bonert; Michal Michal; Ondrej Hes
Journal:  Virchows Arch       Date:  2018-09-19       Impact factor: 4.064

2.  Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.

Authors:  Doreen N Palsgrove; Yunjie Li; Christine A Pratilas; Ming-Tseh Lin; Aparna Pallavajjalla; Christopher Gocke; Angelo M De Marzo; Andres Matoso; George J Netto; Jonathan I Epstein; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2018-09       Impact factor: 6.394

3.  Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.

Authors:  Hui-Zhi Zhang; Qiu-Yuan Xia; Shu-Yan Wang; Meng-Jie Shi; Su-Ying Wang
Journal:  Virchows Arch       Date:  2022-01-31       Impact factor: 4.064

Review 4.  [Oncocytic tumours of the kidney-new differential diagnoses].

Authors:  I Polifka; R Ohashi; H Moch
Journal:  Pathologe       Date:  2021-09-01       Impact factor: 1.011

5.  TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.

Authors:  Anna Caliò; Stefano Marletta; Matteo Brunelli; Serena Pedron; Sofia Canete Portillo; Diego Segala; Elena Bariani; Stefano Gobbo; George Netto; Guido Martignoni
Journal:  Virchows Arch       Date:  2022-08-18       Impact factor: 4.535

6.  Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney.

Authors:  Payal Kapur; Ming Gao; Hua Zhong; Suneetha Chintalapati; Midori Mitui; Spencer D Barnes; Qinbo Zhou; Jeffrey Miyata; Deyssy Carrillo; Venkat S Malladi; Dinesh Rakheja; Ivan Pedrosa; Lin Xu; Lisa Kinch; James Brugarolas
Journal:  Mod Pathol       Date:  2021-09-20       Impact factor: 8.209

Review 7.  [Characterization of different renal cell carcinoma entities].

Authors:  N J Rupp; H Moch
Journal:  Urologe A       Date:  2020-02       Impact factor: 0.639

8.  Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.

Authors:  Ying-Bei Chen; Leili Mirsadraei; Gowtham Jayakumaran; Hikmat A Al-Ahmadie; Samson W Fine; Anuradha Gopalan; S Joseph Sirintrapun; Satish K Tickoo; Victor E Reuter
Journal:  Am J Surg Pathol       Date:  2019-01       Impact factor: 6.394

Review 9.  [Histological subtypes of renal cell carcinoma : Overview and new developments].

Authors:  I Polifka; A Agaimy; H Moch; A Hartmann
Journal:  Pathologe       Date:  2021-04-06       Impact factor: 1.011

10.  Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.

Authors:  Kiril Trpkov; Sean R Williamson; Anthony J Gill; Ondrej Hes; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou
Journal:  Mod Pathol       Date:  2021-02-01       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.